Atherosclerotic plaque (AP) homing nonapeptide (CRKRLDRNC) was identified after cycles of ex vivo phage display screening on human atheroma tissue and further validated for homing to the atherosclerotic plaques in an in vivo murine model. A homology sequence search identified the AP binding sequence KRLDRN motif corresponding to the Interleukin-4 (IL-4) . Its receptor, IL-4R, is abundantly expressed by glioma cells thereby presenting the CRKRLDRNC as a promising tool for glioma targeting. Park et al. showed promising results with the AP peptide conjugated to doxorubicin containing microbubbles and nanoliposomes as a proof-of-concept for glioma targeted imaging and therapy using the U87MG in vitro models. AP peptide conjugated to doxorubicin containing liposomes showed also enhanced antitumor activity in in vivo model of human lung cancer.
储存指南
一般情况下, Interleukin-4 Receptor Targeting多肽 AP 粉末应该保存在-20甚至-70摄氏度. Interleukin-4 Receptor Targeting多肽 AP 溶解后应该-70摄氏度分装保存,避免反复冻融. 了解更多细节,请查阅手册:多肽溶解及保存指南
参考文献
Hong HY, Lee HY, Kwak W, Yoo J, Na MH, So IS, et al. Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis. J Cell Mol Med. 2008;12(5B):2003-14